Our pipeline consists of first-in-class small molecule drugs that affect multiple cell types in the tumor or immune microenvironments. Initial focus is on targets in cancer and autoimmunity where significant unmet medical need is warranted. Lead program with dual MCT1 and MCT4 inhibitors address the fundamental mechanism of metabolic symbiosis between cancer cells and stromal cells in the TME, which includes CAFs, endothelial cells, and immune cells. We are exploring inhibitors for other undisclosed metabolic SLCTs, which have potential to exert both direct anti-tumor activity and anti-tumor immunity. In the absence of the TME, selective MCT inhibitors may play a role in suppressing autoimmunity. Currently, we are testing that hypothesis in rheumatoid arthritis.